<DOC>
	<DOC>NCT01064791</DOC>
	<brief_summary>This study will assess the safety and efficacy of different doses of sotrastaurin when combined with tacrolimus for the prevention of acute rejection after de novo renal transplantation.</brief_summary>
	<brief_title>Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criteria: Recipients of a first or second kidney transplant from a deceased, living unrelated or nonhuman leukocyte antigen (HLA) identical living related donor. Recipients of a kidney with a cold ischemia time &lt; 30 hours. Recipients of a kidney from a donor 10 65 years old. Exclusion criteria: Multiorgan transplant recipients. Recipients of an organ from an nonheart beating donor. Patients receiving a second kidney allograft if the first allograft was Functional for less than three years Patients who are treated with drugs that are strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4) at screening and cannot discontinue this treatment. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Renal transplantation</keyword>
</DOC>